CN117980320A - 白介素-23受体的二环肽抑制剂 - Google Patents

白介素-23受体的二环肽抑制剂 Download PDF

Info

Publication number
CN117980320A
CN117980320A CN202280062001.1A CN202280062001A CN117980320A CN 117980320 A CN117980320 A CN 117980320A CN 202280062001 A CN202280062001 A CN 202280062001A CN 117980320 A CN117980320 A CN 117980320A
Authority
CN
China
Prior art keywords
alkyl
phe
ala
cyano
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280062001.1A
Other languages
English (en)
Chinese (zh)
Inventor
孙程早
S·尼拉姆卡维尔
R·J·帕奇
S·索马尼
S·A·巴罗斯
J·张
C·亨德里克
E·比安基
R·科斯坦特
R·因格尼托
D·布兰卡
A·班达里
B·弗雷德里克
T·T·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Protagonist Therapeutics Inc
Original Assignee
Janssen Biotech Inc
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc, Protagonist Therapeutics Inc filed Critical Janssen Biotech Inc
Publication of CN117980320A publication Critical patent/CN117980320A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
CN202280062001.1A 2021-07-14 2022-07-14 白介素-23受体的二环肽抑制剂 Pending CN117980320A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163221854P 2021-07-14 2021-07-14
US63/221,854 2021-07-14
PCT/US2022/037202 WO2023288017A2 (en) 2021-07-14 2022-07-14 Bicyclic peptide inhibitors of interleukin-23 receptor

Publications (1)

Publication Number Publication Date
CN117980320A true CN117980320A (zh) 2024-05-03

Family

ID=84920518

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280062001.1A Pending CN117980320A (zh) 2021-07-14 2022-07-14 白介素-23受体的二环肽抑制剂

Country Status (12)

Country Link
US (1) US20240352073A1 (cg-RX-API-DMAC7.html)
EP (1) EP4370532A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024525723A (cg-RX-API-DMAC7.html)
KR (1) KR20240034223A (cg-RX-API-DMAC7.html)
CN (1) CN117980320A (cg-RX-API-DMAC7.html)
AR (1) AR126457A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022310347A1 (cg-RX-API-DMAC7.html)
CA (1) CA3226492A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024000761A (cg-RX-API-DMAC7.html)
TW (1) TW202321275A (cg-RX-API-DMAC7.html)
UY (1) UY39858A (cg-RX-API-DMAC7.html)
WO (1) WO2023288017A2 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026026815A1 (zh) * 2024-07-30 2026-02-05 西藏海思科制药有限公司 白介素-23受体的肽抑制剂及其用途
WO2026041110A1 (zh) * 2024-08-22 2026-02-26 上海瀚辰星泰医药科技有限公司 一种多肽化合物及其应用
WO2026138829A1 (zh) * 2024-12-23 2026-07-02 上海医药集团股份有限公司 多肽抑制剂及其应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제
EP4652181A1 (en) * 2023-01-16 2025-11-26 Janssen Pharmaceutica NV Polycyclic peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CN121909205A (zh) 2023-09-08 2026-04-21 赛诺菲 作为选择性il-23受体抑制剂的新型肽
CN121794283A (zh) 2023-09-08 2026-04-03 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2025076414A1 (en) * 2023-10-06 2025-04-10 The Children's Medical Center Corporation Compositions and methods for selecting a subject for inflammatory bowel disease treatment
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201810154WA (en) * 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2016054445A1 (en) * 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
HK1257747A1 (zh) * 2015-07-15 2019-10-25 Protagonist Therapeutics Inc. 白细胞介素-23受体的肽抑制剂以及其治疗炎症性疾病的用途
CA3046171A1 (en) * 2016-12-06 2018-06-14 Stichting Voor De Technische Wetenschappen Multicyclic peptides and methods for their preparation
WO2019034866A1 (en) * 2017-08-14 2019-02-21 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
MX2020006290A (es) * 2017-12-15 2020-12-03 Janssen Biotech Inc Dinucleotidos ciclicos como agonistas de sting.
CA3104418A1 (en) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2020311395A1 (en) * 2019-07-10 2022-02-03 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
TWI860386B (zh) * 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026026815A1 (zh) * 2024-07-30 2026-02-05 西藏海思科制药有限公司 白介素-23受体的肽抑制剂及其用途
WO2026041110A1 (zh) * 2024-08-22 2026-02-26 上海瀚辰星泰医药科技有限公司 一种多肽化合物及其应用
WO2026138829A1 (zh) * 2024-12-23 2026-07-02 上海医药集团股份有限公司 多肽抑制剂及其应用

Also Published As

Publication number Publication date
EP4370532A4 (en) 2025-09-03
KR20240034223A (ko) 2024-03-13
TW202321275A (zh) 2023-06-01
AR126457A1 (es) 2023-10-11
UY39858A (es) 2023-02-28
JP2024525723A (ja) 2024-07-12
WO2023288017A3 (en) 2023-03-09
MX2024000761A (es) 2024-04-18
US20240352073A1 (en) 2024-10-24
WO2023288017A2 (en) 2023-01-19
AU2022310347A1 (en) 2024-02-29
CA3226492A1 (en) 2023-01-19
EP4370532A2 (en) 2024-05-22

Similar Documents

Publication Publication Date Title
CN117999274A (zh) 白介素-23受体的肽抑制剂
JP7441955B2 (ja) インターロイキン23受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用
KR20240034223A (ko) 인터류킨-23 수용체의 바이사이클릭 펩티드 억제제
US12478617B2 (en) Lipidated peptide inhibitors of interleukin-23 receptor
JP7670605B2 (ja) インターロイキン-23受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用
JP2022540154A (ja) インターロイキン-23受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
CN115279782A (zh) 白介素-23受体的肽抑制剂及其用于治疗炎性疾病的用途
WO2021146458A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
HK40131813A (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
HK40111925A (en) Lipidated peptide inhibitors of interleukin-23 receptor
HK40083331A (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination